PODD - Insulet Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
117.72
-2.05 (-1.71%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close119.77
Open119.81
Bid0.00 x 800
Ask0.00 x 1200
Day's Range117.40 - 119.85
52 Week Range70.80 - 122.19
Volume547,578
Avg. Volume634,112
Market Cap7.025B
Beta (3Y Monthly)0.51
PE Ratio (TTM)523.20
EPS (TTM)0.22
Earnings DateJul 31, 2019 - Aug 5, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est106.88
Trade prices are not sourced from all markets
  • Markit10 days ago

    See what the IHS Markit Score report has to say about Insulet Corp.

    Insulet Corp NASDAQ/NGS:PODDView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is high * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NegativeShort interest is high for PODD with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting PODD. However, the last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold PODD had net inflows of $1.72 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Did Hedge Funds Drop The Ball On Insulet Corporation (PODD) ?
    Insider Monkey11 days ago

    Did Hedge Funds Drop The Ball On Insulet Corporation (PODD) ?

    Before putting in our own effort and resources into finding a good investment, we can quickly utilize hedge fund expertise to give us a quick glimpse of whether that stock could make for a good addition to our portfolios. The odds are not exactly stacked in investors' favor when it comes to beating the market, […]

  • Insulet (PODD) Hits 52-Week High on Solid Growth Prospects
    Zacks12 days ago

    Insulet (PODD) Hits 52-Week High on Solid Growth Prospects

    Insulet (PODD) gains from steady global expansion as well as rollout of innovative products like Omnipod DASH and Omnipod Horizon automated insulin delivery system.

  • What Are Insulet’s Key Growth Drivers in 2019?
    Market Realist14 days ago

    What Are Insulet’s Key Growth Drivers in 2019?

    Tandem Diabetes Care or Insulet: Which Is a Better Pick in June?(Continued from Prior Part)Improving payer accessIn the first quarter, Insulet (PODD) secured coverage for its Omnipod devices for 5 million Medicare and Medicaid members. According to

  • Tandem or Insulet: Who Is Reporting Faster Pump Uptake?
    Market Realist14 days ago

    Tandem or Insulet: Who Is Reporting Faster Pump Uptake?

    Tandem Diabetes Care or Insulet: Which Is a Better Pick in June?(Continued from Prior Part)Tandem Diabetes Care’s pump demandIn the first quarter, Tandem Diabetes Care (TNDM) shipped 14,700 insulin pumps, a YoY rise of 232%. The demand rose

  • Tandem Diabetes and Insulet: Comparing Revenue Growth
    Market Realist15 days ago

    Tandem Diabetes and Insulet: Comparing Revenue Growth

    Tandem Diabetes Care or Insulet: Which Is a Better Pick in June?(Continued from Prior Part)Tandem Diabetes Care’s revenue trajectoryIn its first-quarter earnings conference call, Tandem Diabetes Care (TNDM) increased its fiscal 2019 revenue

  • How Analysts Rate Tandem Diabetes Care and Insulet
    Market Realist15 days ago

    How Analysts Rate Tandem Diabetes Care and Insulet

    Tandem Diabetes Care or Insulet: Which Is a Better Pick in June?Evolving insulin delivery landscapeUntil the start of 2017, the insulin pump technology space was mainly dominated by big companies such as Medtronic (MDT) and Johnson & Johnson

  • Business Wire15 days ago

    Insulet’s Omnipod® Horizon™ Hybrid Closed-Loop System Improves Glycemic Control in Patients as Young as Two Years Old with Type 1 Diabetes

    Insulet Corporation (PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced that positive results from the most recent clinical trial of the Omnipod® Horizon™ Automated Insulin Delivery System (Omnipod Horizon System) were presented during the American Diabetes Association (ADA) 79th Scientific Sessions in San Francisco, California.

  • Business Wire19 days ago

    Insulet to Showcase its Recently-Launched Omnipod® DASH™ System and Present Seven Scientific Abstracts at the American Diabetes Association's 79th Scientific Sessions

    No-Cost Personal Diabetes Manager, No Four Year Lock-in Period, and New User Interface Allow for Smooth Transition from Multiple Daily Injections to Pod Therapy

  • Why Diabetes Stock Insulet Soared 27.3% in May
    Motley Fool21 days ago

    Why Diabetes Stock Insulet Soared 27.3% in May

    Shares of the leader in tubeless insulin pump technology continued their upward climb last month.

  • Insulet (PODD) Up 27.8% Since Last Earnings Report: Can It Continue?
    Zacks24 days ago

    Insulet (PODD) Up 27.8% Since Last Earnings Report: Can It Continue?

    Insulet (PODD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • How IBD Called The Stock Market Correction Quickly — And Where It May Go From Here
    Investor's Business Daily26 days ago

    How IBD Called The Stock Market Correction Quickly — And Where It May Go From Here

    This week's podcast discussion is all about vertical violations, which can be used to spot a potentially prolonged stock market correction.

  • Thomson Reuters StreetEvents27 days ago

    Edited Transcript of PODD earnings conference call or presentation 2-May-19 8:30pm GMT

    Q1 2019 Insulet Corp Earnings Call

  • Business Wirelast month

    Insulet to Present at Upcoming Investor Conferences

    Insulet Corporation , the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, today announced that management wil

  • GuruFocus.comlast month

    Insulet and West Pharma Proven Winners in Growing Wearable Devices Market

    With rapid growth projected for the market for wearable drug delivery devices, investors would be wise to consider some of the key players in the business. Two standouts are Boston-area-based Insulet (PODD) and West Pharmaceutical Services (WST), which is headquartered in Exton, Pennsylvania. Warning! GuruFocus has detected 4 Warning Signs with PODD.

  • Motley Foollast month

    Insulet and Novocure Are Going Gangbusters

    These two medical-device gems posted record results in the first quarter that send their stocks shooting higher.

  • Motley Fool2 months ago

    2 Winners and 2 Losers in the Med Tech Market This Quarter

    Medical devices can be ultra reliable, lucrative business, but there are plenty of ways for companies to blow it, too.

  • Insulet Kicks Off 2019 With a Strong Quarter; Stock Soars 12%
    Motley Fool2 months ago

    Insulet Kicks Off 2019 With a Strong Quarter; Stock Soars 12%

    In the first quarter, the tubeless insulin pump specialist's revenue growth accelerated and it raised its full-year 2019 guidance.

  • Why Diabetes-Disruptor Insulet Is Skyrocketing 10% Today
    Motley Fool2 months ago

    Why Diabetes-Disruptor Insulet Is Skyrocketing 10% Today

    The insulin pump maker reported better-than-expected first-quarter financials and issued a rosier outlook for 2019.

  • Should You Be Worried About Insulet Corporation's (NASDAQ:PODD) 1.6% Return On Equity?
    Simply Wall St.2 months ago

    Should You Be Worried About Insulet Corporation's (NASDAQ:PODD) 1.6% Return On Equity?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Many investors are still learning about the various metrics that can be useful when analysing a stock...

  • Insulet Corp (PODD) Q1 2019 Earnings Call Transcript
    Motley Fool2 months ago

    Insulet Corp (PODD) Q1 2019 Earnings Call Transcript

    PODD earnings call for the period ending March 31, 2019.

  • Insulet (PODD) Beats Earnings and Revenue Estimates in Q1
    Zacks2 months ago

    Insulet (PODD) Beats Earnings and Revenue Estimates in Q1

    Insulet (PODD) registers year-over-year improvement in revenues on solid uptake of Omnipod system both in the United States and international markets.